Acute vascular rejection and accommodation: Divergent outcomes of the humoral response to organ transplantation

Transplantation

Volumn 78, Issue 10, 2004, Pages 1471-1478

  Williams, Josie M ^a   Holzknecht, Zoie E ^b   Plummer, Timothy B ^a   Lin, Shu S ^b   Brunn, Gregory J ^a   Platt, Jeffrey L ^a  

^a MAYO CLINIC   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Accommodation; Cardiac transplant; Humoral rejection; Rejection

Indexed keywords

COMPLEMENT; HEPARAN SULFATE; SYNDECAN 4;

ACUTE GRAFT REJECTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; ANTIGEN BINDING; ARTICLE; BABOON; BLOOD VESSEL; COMPLEMENT ACTIVATION; CONTROLLED STUDY; GENE EXPRESSION; HEART GRAFT; HUMORAL IMMUNITY; NONHUMAN; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SWINE; XENOGRAFT;

ACUTE DISEASE; ANIMALS; ANTIBODIES, HETEROPHILE; ANTIBODY FORMATION; APOPTOSIS; B-LYMPHOCYTES; BASE SEQUENCE; COMPLEMENT ACTIVATION; DNA PRIMERS; GRAFT REJECTION; HEART TRANSPLANTATION; PAPIO; POLYMERASE CHAIN REACTION; RNA; SWINE; TRANSPLANTATION, HETEROLOGOUS; TREATMENT OUTCOME;

EID: 9244246781     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000140770.81537.64     Document Type: Article

References (50)

1. Kissmeyer-Nielsen F, Olsen S, Petersen VP, et al. Hyperacute rejection of kidney allografts, associated with pre-existing humoral antibodies against donor cells. Lancet 1966; 2: 662.
2. Lederer SR, Schneeberger H, Albert E, et al. Early renal graft dysfunction. The role of preformed antibodies to DR-typed lymphoblastoid cell lines. Transplantation 1996; 61: 313.
3. Trpkov K, Campbell P, Pazderka F, et al. Pathologic features of acute renal allograft rejection associated with donor-specific antibody. Transplantation 1996; 61: 1586.
4. Lin SS, Weidner BC, Byrne GW, et al. The role of antibodies in acute vascular rejection of pig-to-baboon cardiac transplants. J Clin Invest 1998; 101: 1745.
5. Rose EA, Smith CR, Petrossian GA, et al. Humoral immune responses after cardiac transplantation: correlation with fatal rejection and graft atherosclerosis. Surgery 1989; 106: 203.
6. Dunn MJ, Crisp SJ, Rose ML, et al. Anti-endothelial antibodies and coronary artery disease after cardiac transplantation. Lancet 1992; 339: 1566.
7. Russell PS, Chase CM, Winn HJ, et al. Coronary atherosclerosis in transplanted mouse hearts. II. Importance of humoral immunity. J Immunol 1994; 152: 5135.
8. Platt JL, Vercellotti GM, Dalmasso AP, et al. Transplantation of discordant xenografts: a review of progress. Immunol Today 1990; 11: 450.
9. Platt JL. New directions for organ transplantation. Nature 1998; 392(Suppl): 11.
10. Mohiuddin MM, Ogawa H, Yin DP, et al. Antibody-mediated accommodation of heart grafts expressing an incompatible carbohydrate antigen. Transplantation 2003; 75: 258.
11. Yuzawa Y, Brentjens JR, Brett J, et al. Antibody-mediated redistribution and shedding of endothelial antigens in the rabbit. J Immunol 1993; 150: 5633.
12. Lin Y, Vandeputte M, Waer M. Accommodation and T-independent B cell tolerance in rats with long term surviving hamster heart xenografts. J Immunol 1998; 160: 369.
13. Cascalho M, Platt JL. The immunological barrier to xenotransplantation. Immunity 2001; 14: 437.
14. Leventhal JR, Dalmasso AP, Cromwell JW, et al. Prolongation of cardiac xenograft survival by depletion of complement. Transplantation 1993; 55: 857.
15. Magee JC, Collins BH, Harland RC, et al. Immunoglobulin prevents complement mediated hyperacute rejection in swine-to-primate xenotransplantation. J Clin Invest 1995; 96: 2404.
16. Byrne GW, McCurry KR, Martin MJ, et al. Transgenic pigs expressing human CD59 and decay-accelerating factor produce an intrinsic barrier to complement-mediated damage. Transplantation 1997; 63: 149.
17. Cozzi E, Yannoutsos N, Langford GA, et al. Effect of transgenic expression of human decay-accelerating factor on the inhibition of hyperacute rejection of pig organs. In: Cooper DKC, Kemp E, Platt JL, White DJG, eds. Xenotransplantation: the transplantation of organs and tissues between species. Berlin, Springer 1997, pp 665.
18. Lin SS, Hanaway MJ, Gonzalez-Stawinski GV, et al. The role of anti-Galα1-3Gal antibodies in acute vascular rejection and accommodation of xenografts. Transplantation (Rapid Communication) 2000; 70: 1667.
19. Schwartz ME, Podesta L, Morris M, et al. Donor management, techniques and procurement. In: Makowka L, ed. The handbook of transplantation management. Austin, R.G. Landes Co. 1991, pp 44.
20. McCurry KR, Parker W, Cotterell AH, et al. Humoral responses in pig-to-baboon cardiac transplantation: implications for the pathogenesis and treatment of acute vascular rejection and for accommodation. Hum Immunol 1997; 58: 91.
21. Parker W, Bruno D, Holzknecht ZE, et al. Characterization and affinity isolation of xenoreactive human natural antibodies. J Immunol 1994; 153: 3791.
22. Yu PB, Holzknecht ZE, Bruno D, et al. Modulation of natural IgM binding and complement activation by natural IgG antibodies. J Immunol 1996; 157: 5163.
23. Holzknecht ZE, Kuypers KL, Plummer TB, et al. Apoptosis and cellular activation in the pathogenesis of acute vascular rejection. Circ Res 2002; 91: 1135.
24. Klein NJ, Shennan GI, Heyderman RS, et al. Detection of glycosaminoglycans on the surface of human umbilical vein endothelial cells using gold-conjugated poly-L-lysine with silver enhancement. Histochem J 1993; 25: 291.
25. Bannett AD, McAlack RF, Morris M, et al. ABO incompatible renal transplantation: a qualitative analysis of native endothelial tissue ABO antigens after transplant. Transplant Proc 1989; 21: 783.
26. Lin SS, Parker W, Everett ML, et al. Differential recognition by proteins of α-galactosyl residues on endothelial cell surfaces. Glycobiology 1998; 8: 433.
27. Foreman KE, Vaporciyan AA, Bonish BK, et al. C5a-induced expression of p-selectin in endothelial cells. J Clin Invest 1994; 94: 1147.
28. Saadi S, Holzknecht RA, Patte CP, et al. Complement-mediated regulation of tissue factor activity in endothelium. J Exp Med 1995; 182: 1807.
29. Saadi S, Holzknecht RA, Patte CP, et al. Endothelial cell activation by pore forming structures: pivotal role for IL-1α. Circulation 2000; 101: 1867.
30. Palmetshofer A, Galili U, Dalmasso AP, et al. Alpha-galactosyl epitope-mediated activation of porcine aortic endothelial cells: type II activation. Transplantation 1998; 65: 971.
31. Alwayn IPJ, Buhler L, Appel III JZ, et al. Mechanisms of thrombotic microangiopathy following xenogeneic hematopoietic progenitor cell transplantation. Transplantation 2001; 71: 1601.
32. Dalmasso AP, Benson BA, Johnson JS, et al. Resistance against the membrane attack complex of complement induced in porcine endothelial cells with a Gal alpha(1-3)Gal binding lectin: up-regulation of CD59 expression. J Immunol 2000; 164: 3764.
33. Soares MP, Lin Y, Anrather J, et al. Expression of heme oxygenase-1 can determine cardiac xenograft survival. Nat Med 1998; 4: 1073.
34. Sato K, Balla J, Otterbein L, et al. Carbon monoxide generated by heme oxygenase-1 suppresses the rejection of mouse-to-rat cardiac transplants. J Immunol 2001; 166: 4185.
35. Dempsey LA, Brunn GJ, Platt JL. Heparanase, a potential regulator of cell-matrix interactions. Trends Biochem Sci 2000; 25: 349.
36. Saadi S, Wrenshall LE, Platt JL. Regional manifestations and control of the immune system. FASEB J 2002; 16: 849.
37. Platt JL, Vercellotti GM, Lindman BJ, et al. Release of heparan sulfate from endothelial cells. Implications for pathogenesis of hyperacute rejection. J Exp Med 1990; 171: 1363.
38. Gotte M. Syndecans in inflammation. FASEB J 2003; 17: 575.
39. Franke TF, Hornik CP, Segev L, et al. PI3K/Akt and apoptosis: size matters. Oncogene 2003; 22: 8983.
40. Carney DF, Lang TJ, Shin ML. Multiple signal messengers generated by terminal complement complexes and their role in terminal complement complex elimination. J Immunol 1990; 145: 623.
41. Dorling A, Stocker C, Tsao T, et al. In vitro accommodation of immortalized porcine endothelial cells: resistance to complement mediated lysis and down-regulation of VCAM expression induced by low concentrations of polyclonal human IgG antipig antibodies. Transplantation 1996; 62: 1127.
42. 2+. J Immunol 1986; 137: 263.
43. Peng H, Takano T, Papillon J, et al. Complement activates the c-Jun N-terminal kinase/stress-activated protein kinase in glomerular epithelial cells. J Immunol 2002; 169: 2594.
44. Diamond LE, McCurry KR, Oldham ER, et al. Characterization of transgenic pigs expressing functionally active human CD59 on cardiac endothelium. Transplantation 1996; 61: 1241.
45. Weiler JM, Edens RE, Linhardt RJ, et al. Heparin and modified heparin inhibit complement activation in vivo. J Immunol 1992; 148: 3210.
46. Edens RE, Linhardt RJ, Bell CS, et al. Heparin and derivatized heparin inhibit zymosan and cobra venom factor activation of complement in serum. Immunopharmacology 1994; 27: 145.
47. Park W, Grande JP, Ninova D, et al. Accommodation in ABO-incompatible kidney allografts, a novel mechanism of self-protection against antibody-mediated injury. Am J Transplant 2003; 3: 952.
48. Yang Y, Yu X. Regulation of apoptosis: the ubiquitous way. FASEB J 2003; 17: 790.
49. Takemoto SK, Zeevi A, Feng S, et al. A national conference to assess antibody mediated rejection in solid organ transplantation. Am J Transplant, 2004; 4: 1033.
50. Platt JL. C4d and the fate of organ allografts. J Am Soc Nephrol 2002; 13: 2417.